To define the mean time of first recurrence of diabetic macular edema (DME) after a single injection of dexamethasone intravitreal implant (DEX-I), reducing the burden of monthly visits during a PRN regimen of treatment.
Methods
Twenty phakic eyes with DME (12 eyes naïve and 8 eyes with edema persistent after previous treatments) were followed monthly after DEX-I injection until evidence of first recurrence of edema, defined as a change in visual acuity (VA) ≥5 letters and/or in foveal thickness (FT) ≥50 µm. Reaching this point, the eyes were re-treated. Monitored parameters were changes in VA, FT, intraocular pressure (IOP), and lens opacity.
Results
Maximal efficacy was registered at month 1, when mean VA improved by 14 letters (19%), FT decreased by 325 µm (43.7%), and in 15 eyes (75%) edema was completely reabsorbed. The mean time of first recurrence was 5.1 months. No statistical difference was found between eyes with naïve or persistent DME. Five eyes needed topical medication for modest temporary IOP increase (21-24 mm Hg) between months 2 and 4. No increase in lens opacities was registered during follow-up.
Conclusions
According to the results of this study, the first signs of DME recurrence after DEX-I injection appear at a mean time of 5 months, suggesting that an appropriate and prudent time schedule for a PRN regimen could be limited to monthly tonometry and a first complete examination not before 4 months.
Get full access to this article
View all access options for this article.
References
1.
HallerJABandelloFBelfortRJrOZURDEX GENEVA Study GroupRandomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–46.
2.
LowderCBelfortRJrLightmanSOzurdex HURON Study GroupDexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.
3.
KuppermannBDBlumenkranzMSHallerJADexamethasone DDS Phase II Study GroupRandomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–17.
4.
HallerJAKuppermannBDBlumenkranzMSDexamethasone DDS Phase II Study GroupRandomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–96.
5.
CallananDGGuptaSBoyerDSOzurdex PLACID Study GroupDexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843–51.
6.
Dutra MedeirosMPostorinoMNavarroRGarcia-ArumíJMateoCCorcósteguiBDexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231:141–6.
7.
LazicRLukicMBorasITreatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34:719–24.
8.
PacellaEVestriARMuscellaRPreliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7:1423–8.
9.
RishiPRishiEKuniyalLMathurGShort-term results of intravitreal dexamethasone implant (OZURDEX®) in treatment of recalcitrant diabetic macular edema: a case series. Oman J Ophthalmol. 2012;5:79–82.
10.
ZucchiattiILattanzioRQuerquesGIntravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228:117–22.
11.
SakamotoANishijimaKKitaMOhHTsujikawaAYoshimuraN; Ozurdex CHAMPLAIN Study GroupAssociation between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1325–30.
12.
Sanz-MarcoEUdaondoPFrances-MuñozEGallego-PinazoRDiaz-LlopisMRe: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2012;32:1695–6 author reply 1696-7.
13.
Chang-LinJEBurkeJAPengQPharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52:4605–9.
14.
Early Treatment Diabetic Retinopathy Study Research GroupPhotocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1Arch Ophthalmol. 1985;103:1796–806.
15.
ChylackLTJrWolfeJKSingerDMThe Longitudinal Study of Cataract Study GroupThe lens opacities classification system III. Arch Ophthalmol. 1993;111:831–6.
16.
HallerJADugelPWeinbergDVChouCWhitcupSMEvaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29:46–51.
17.
BhagatNGrigorianRATutelaAZarbinMADiabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32.
18.
OtaniTYamaguchiYKishiSCorrelation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010;30:774–80.
19.
FerrisFLIIIPatzAMacular edema: a complication of diabetic retinopathy. Surv Ophthalmol. 1984; 28(Suppl): 452–61.
20.
MiyamotoKKhosrofSBursellSEPrevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836–41.
21.
TamuraHMiyamotoKKiryuJIntravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46:1440–4.
22.
FunatsuHNomaHMimuraTEguchiSHoriSAssociation of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–9.
23.
AntcliffRJMarshallJThe pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32.
24.
WangJXuXElliottMHZhuMLeYZMüller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59:2297–305.
25.
GroverDLiTJChongCCIntravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;1:CD005656.
26.
WangKWangYGaoLLiXLiMGuoJDexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008;31:1541–6.
27.
AntonettiDAWolpertEBDeMaioLHarhajNSScadutoRCJrHydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80:667–77.
28.
FelinskiEAAntonettiDAGlucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30:949–57.
29.
CampochiaroPABrownDMPearsonAFAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.
30.
DewanVLambertDEdlerJKymesSApteRSCost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2012;119:1679–84.
31.
CiullaTAWalkerJDFongDSCriswellMHCorticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15:211–20.
32.
AvitabileTLongoAReibaldiAIntravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695–702.
33.
JonasJBKamppeterBAHarderBVossmerbaeumerUSauderGSpandauUHIntravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther. 2006;22:200–7.
